38% rise for head of Zeneca
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir David Barnes, chief executive of Zeneca, saw his total pay jump 38 per cent to pounds 898,000 last year. The rise rounds off a year of personal success for the executive head of Britain's third-biggest drugs group.
He also received a knighthood "for services to the pharmaceutical industry" last year and saw Zeneca's profits exceed pounds 1bn for the first time.
Writing in the latest annual report, Sir Sydney Lipworth, chairman, said: "David has been tireless in his endeavours to develop Zeneca and his contribution to both the company the industry has been profound."
Sir David's basic pay of pounds 525,000 was supplemented by cash and share bonuses totalling pounds 315,000 and a pounds 46,000 pension contribution. His pay has some way to go yet to match that of Jan Leschly, his opposite number at rival drugs group SmithKline Beecham, who saw his total emoluments rise 15 per cent to pounds 2.52m last year.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments